Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017

DOI Web Site 被引用文献1件
  • Simon Yadgir
    Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
  • Catherine Owens Johnson
    Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
  • Victor Aboyans
    Department of Cardiology, Dupuytren University Hospital, Limoges, France (V. Aboyans).
  • Oladimeji M. Adebayo
    College of Medicine, University College Hospital, College of Medicine, University College Hospital, Ibadan, Oyo, Nigeria (O.M.A.).
  • Rufus Adesoji Adedoyin
    Department of Medical Rehabilitation, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria (R.A.A.).
  • Mohsen Afarideh
    Endocrinology and Metabolism Research Center (M.A., A.E.), Tehran University of Medical Sciences, Iran.
  • Fares Alahdab
    Evidence Based Practice Center, Mayo Clinic Foundation for Medical Education and Research, Rochester, MN (F.A.).
  • Alaa Alashi
    Department of Cardiovascular Medicine (A.A., M.M.G.), Cleveland Clinic, OH.
  • Vahid Alipour
    Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran.
  • Jalal Arabloo
    Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran.
  • Samad Azari
    Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran.
  • Celine M. Barthelemy
    Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
  • Catherine P. Benziger
    Heart and Vascular Center, Essentia Health, Duluth, MN (C.P.B.).
  • Adam E. Berman
    Department of Medicine, Medical College of Georgia at Augusta University (A.E.B.).
  • Ali Bijani
    Social Determinants of Health Research Center, Babol University of Medical Sciences, Mazandaran, Iran (A.B.).
  • Juan J. Carrero
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (J.J.C.).
  • Félix Carvalho
    Applied Molecular Biosciences Unit (F.C.), University of Porto, Portugal.
  • Ahmad Daryani
  • Andre R. Durães
    Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran (A.D.).
  • Alireza Esteghamati
    Endocrinology and Metabolism Research Center (M.A., A.E.), Tehran University of Medical Sciences, Iran.
  • Talha A. Farid
    Division of Cardiovascular Medicine, University of Louisville, KY (T.A.F., A.R.K.).
  • Farshad Farzadfar
    Non-communicable Diseases Research Center (F.F.), Tehran University of Medical Sciences, Iran.
  • Eduarda Fernandes
    REQUIMTE/LAQV (E.F.), University of Porto, Portugal.
  • Irina Filip
    Psychiatry Department, Kaiser Permanente, Fontana, CA (I.F.).
  • Mohamed M. Gad
    Department of Cardiovascular Medicine (A.A., M.M.G.), Cleveland Clinic, OH.
  • Samer Hamidi
    School of Health and Environmental Studies, Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates (S.H.).
  • Simon I. Hay
    Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
  • Olayinka Stephen Ilesanmi
    Department of Community Medicine, University of Ibadan, Nigeria (O.S.I.).
  • Seyed Sina Naghibi Irvani
    Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran (S.S.N.I.).
  • Mikk Jürisson
    Institute of Family Medicine and Public Health, University of Tartu, Tartumaa, Estonia (M.J.).
  • Amir Kasaeian
    Hematology-Oncology and Stem Cell Transplantation Research Center (A. Kasaeian), Tehran University of Medical Sciences, Iran.
  • Andre Pascal Kengne
    Non-communicable Diseases Research Unit, Medical Research Council South Africa, Cape Town (A.P.K.).
  • Abdur Rahman Khan
    Division of Cardiovascular Medicine, University of Louisville, KY (T.A.F., A.R.K.).
  • Adnan Kisa
    Department of Health Management and Health Economics, Kristiania University College, Oslo, Norway (A. Kisa).
  • Sezer Kisa
    Department of Nursing and Health Promotion, Oslo Metropolitan University, Norway (S.K.).
  • Dhaval Kolte
    Department of Medicine, Brown University, Providence, RI (D.K.).
  • Navid Manafi
    Ophthalmology Department (N.M.), Iran University of Medical Sciences, Tehran.
  • Amir Manafi
    Department of Surgery, University of Virginia, Charlottesville (A.M.).
  • George A. Mensah
    Department of Medicine, University of Cape Town, South Africa (A.P.K., G.A.M., K.S.).
  • Erkin M. Mirrakhimov
    Faculty of General Medicine, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan (E.M.M.).
  • Yousef Mohammad
    Internal Medicine Department, King Saud University, Riyadh, Saudi Arabia (Y.M.).
  • Ali H. Mokdad
    Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
  • Ruxandra Irina Negoi
    Anatomy and Embryology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania (R.I.N.).
  • Huong Lan Thi Nguyen
    Institute for Global Health Innovations, Duy Tan University, Hanoi, Vietnam (H.L.T.N.).
  • Trang Huyen Nguyen
    Center of Excellence in Behavioral Health, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam (T.H.N.).
  • Molly R. Nixon
    Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
  • Catherine M. Otto
    Division of Cardiology (C.M.O., G.A.R.), University of Washington, Seattle.
  • Shanti Patel
    Department of Medicine, Maimonides Medical Center, Brooklyn, NY (S.P.).
  • Thomas Pilgrim
    Department of Cardiology, University of Bern, Switzerland (T.P.).
  • Amir Radfar
    College of Graduate Health Sciences, A.T. Still University, Mesa, AZ (A. Radfar).
  • David Laith Rawaf
    WHO Collaborating Centre for Public Health Education and Training (D.L.R.), Imperial College London, United Kingdom.
  • Salman Rawaf
    Department of Primary Care and Public Health (S.R.), Imperial College London, United Kingdom.
  • Wasiq Faraz Rawasia
    Cardiovascular Medicine, West Virginia University, Morgantown (W.F.R.).
  • Aziz Rezapour
    Health Management and Economics Research Center (V. Alipour, J.A., S.A., A. Rezapour), Iran University of Medical Sciences, Tehran.
  • Leonardo Roever
    Department of Clinical Research, Federal University of Uberl ândia, Brazil (L.R.).
  • Anas M. Saad
    Faculty of Medicine, Ain Shams University, Cairo, Egypt (A.M.S.).
  • Seyedmohammad Saadatagah
    Department of Cardiology (S. Saadatagah), Tehran University of Medical Sciences, Iran.
  • Subramanian Senthilkumaran
    Emergency Department, Manian Medical Centre, ERODE, Tamil Nadu, India (S. Senthilkumaran).
  • Karen Sliwa
    Department of Medicine, University of Cape Town, South Africa (A.P.K., G.A.M., K.S.).
  • Berhe Etsay Tesfay
    Department of Public Health, Adigrat University, Tigray, Ethiopia (B.E.T.).
  • Bach Xuan Tran
    Department of Health Economics, Hanoi Medical University, Vietnam (B.X.T.).
  • Irfan Ullah
    Gomal Center of Biochemistry and Biotechnology, Gomal University, Faisalabad, Pakistan (I.U.).
  • Muthiah Vaduganathan
    Heart and Vascular Center, Harvard University, Boston, MA (M.V.).
  • Tommi Juhani Vasankari
    UKK Institute, Tampere, Finland (T.J.V.).
  • Charles D.A. Wolfe
    School of Population Health & Environmental Sciences, King’s College London, United Kingdom (C.D.A.W.).
  • Naohiro Yonemoto
    Department of Psychopharmacology, National Center of Neurology and Psychiatry, Tokyo, Japan (N.Y.).
  • Gregory A. Roth
    Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.

抄録

<jats:sec> <jats:title>Background:</jats:title> <jats:p>Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations. Geospatial statistical methods were used to estimate disease for all countries, because data on nonrheumatic valvular diseases are extremely limited for some regions of the world, such as Sub-Saharan Africa and South Asia. Results accounted for estimated level of disease severity as well as the estimated availability of valve repair or replacement procedures. DALYs and other measures of health-related burden were generated for both sexes and each 5-year age group, location, and year from 1990 to 2017.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Globally, CAVD and degenerative mitral valve disease caused 102 700 (95% uncertainty interval [UI], 82 700–107 900) and 35 700 (95% UI, 30 500–42 500) deaths, and 12.6 million (95% UI, 11.4 million–13.8 million) and 18.1 million (95% UI, 17.6 million–18.6 million) prevalent cases existed in 2017, respectively. A total of 2.5 million (95% UI, 2.3 million–2.8 million) DALYs were estimated as caused by nonrheumatic valvular diseases globally, representing 0.10% (95% UI, 0.09%–0.11%) of total lost health from all diseases in 2017. The number of DALYs increased for CAVD and degenerative mitral valve disease between 1990 and 2017 by 101% (95% UI, 79%–117%) and 35% (95% UI, 23%–47%), respectively. There is significant geographic variation in the prevalence, mortality rate, and overall burden of these diseases, with highest age-standardized DALY rates of CAVD estimated for high-income countries.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>These global and national estimates demonstrate that CAVD and degenerative mitral valve disease are important causes of disease burden among older adults. Efforts to clarify modifiable risk factors and improve access to valve interventions are necessary if progress is to be made toward reducing, and eventually eliminating, the burden of these highly treatable diseases.</jats:p> </jats:sec>

収録刊行物

  • Circulation

    Circulation 141 (21), 1670-1680, 2020-05-26

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ